We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Seegene

Seegene

  Gold Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





AACC Launches COVID-19 Immunity Study at 2021 Annual Scientific Meeting and Clinical Lab Expo

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is launching the COVID-19 Immunity Study, which will examine immune responses to SARS-CoV-2 vaccination or prior infection in a diverse group of volunteers.

Despite continued efforts by the scientific community to understand all aspects of COVID-19, it is still not known how long the currently available SARS-CoV-2 vaccines can provide protection against the SARS-CoV-2 virus. In order to gain further insights into this issue, AACC’s study will also further examine the utility of serologic tests as a means to measure lasting immunity.

AACC will collect blood samples for the planned study from attendees and exhibitors at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held in Atlanta on September 28-30. All study participants must be 18 years of age and efforts will be made to ensure that the research cohort is as diverse as possible. This approach to sample collection is modeled after AACC’s Universal Sample Bank program, which used samples from attendees of the 2015 AACC Annual Scientific Meeting in support of important research related to troponin. People who are unable to attend the meeting in person can also contribute to the study by submitting answers to a 10-minute COVID-19 health questionnaire. In return for donating blood, the study participants will receive the results of their individual antibody profile tests after all the collected samples have been analyzed.

Related Links:
American Association for Clinical Chemistry

Gold Supplier
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Silver Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Laboratory Information System (LIS)
GLIMS 10
New
Silver Supplier
SARS-CoV-2 RT-PCR Assay
Savvygen SARS-CoV-2 Plus

Print article
AACC

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.